Fragmentation for measuring methylation and disease
US12258634B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 6, 2023 |
| Grant date | Mar 25, 2025 |
| Priority date | — |
| Expiry date | Mar 6, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/154
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Fragmentation of cell-free DNA molecules is measured and used for various purposes, including determining methylation, e.g., at a particular site of a DNA molecule, at a particular genomic site in a reference genome for a biological sample (e.g., plasma, serum, urine, saliva) of cell-free DNA of a subject, or for a particular region in the reference genome for the biological sample (also just referred to as a sample). Various types of fragmentation measurements can be used, e.g., end motifs and cleavage profiles. Another purpose is determining a fractional concentration of DNA of a particular tissue type (e.g., clinically-relevant DNA). Another purpose is determining a pathology of a subject using a biological sample including cell-free DNA. The cell-free DNA can be of the subject or of a pathogen (e.g., a virus) in the subject's sample. Sites/regions that are hypermethylated, hypomethylated, 5hmC-enriched, and 5hmC-depleted for a particular tissue type can be used.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.